S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q2 2023

Baker Bros Advisors

Period: Q2 2023 Β· Filed: 2023-08-14
View on SEC EDGAR β†—
AUM
$17.28B
Total portfolio value
Positions
107
Reported securities
Top Holding
SGEN
49.6% $8.57B
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2023-08-14) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
SGENSeagen Inc.$8.57B49.63%β€”β€”
49.6%
INCYIncyte Corporation$2.25B13.03%$62.25$116.86+87.7%
13.0%
ONCBeiGene, Ltd.$2.08B12.04%$178.30$297.65+66.9%
12.0%
ACADACADIA Pharmaceuticals Inc.$1.03B5.94%$23.95$25.97+8.4%
5.9%
MDGLMadrigal Pharmaceuticals, Inc.$356.9M2.07%$231.00$528.10+128.6%
2.1%
BMRNBioMarin Pharmaceutical Inc.$330.3M1.91%$86.68$58.99-31.9%
1.9%
IMCRImmunocore Holdings plc$151.1M0.87%$59.96$32.50-45.8%
0.9%
Invitae Corporation$135.0M0.78%β€”β€”
0.8%
KODKodiak Sciences Inc.$119.4M0.69%$6.90$38.54+458.6%
0.7%
AKROAkero Therapeutics, Inc.$110.6M0.64%β€”β€”
0.6%
ARGXargenx SE$109.2M0.63%$389.73$939.68+141.1%
0.6%
RYTMRhythm Pharmaceuticals, Inc.$107.2M0.62%$16.49$114.17+592.4%
0.6%
REPLReplimune Group, Inc.$106.3M0.62%$23.22$11.58-50.1%
0.6%
ABCLAbCellera Biologics Inc.$106.3M0.62%$6.46$8.11+25.5%
0.6%
KYMRKymera Therapeutics, Inc.$100.6M0.58%$22.99$113.51+393.7%
0.6%
ROIVRoivant Sciences Ltd.$95.0M0.55%$10.08$35.13+248.5%
0.6%
BCRXBioCryst Pharmaceuticals, Inc.$89.5M0.52%$7.04$9.84+39.8%
0.5%
SWTXSpringWorks Therapeutics, Inc.$78.7M0.46%β€”β€”
0.5%
TRDAEntrada Therapeutics, Inc.$73.7M0.43%$15.14$7.72-49.0%
0.4%
RVMDRevolution Medicines, Inc.$72.0M0.42%$26.75$189.24+607.4%
0.4%
IMTXImmatics N.V.$65.1M0.38%$11.54$9.95-13.8%
0.4%
KDNYChinook Therapeutics, Inc.$55.9M0.32%β€”β€”
0.3%
MRTXMirati Therapeutics, Inc.$50.9M0.29%β€”β€”
0.3%
DICEDICE Therapeutics, Inc.$48.1M0.28%β€”β€”
0.3%
BMEABiomea Fusion, Inc.$46.3M0.27%$21.95$1.41-93.6%
0.3%
PRLDPrelude Therapeutics Inc.$45.6M0.26%$4.50$4.91+9.1%
0.3%
DNLIDenali Therapeutics Inc.$43.0M0.25%$29.51$25.83-12.5%
0.3%
KNSAKiniksa Pharmaceuticals, Ltd.$39.6M0.23%$14.08$64.53+358.3%
0.2%
CERSCerus Corporation$39.5M0.23%$2.46$3.16+28.5%
0.2%
NRIXNurix Therapeutics, Inc.$38.8M0.22%$9.99$23.97+139.9%
0.2%

Quarter-on-Quarter Activity

Q2 2023 vs. Q1 2023

New Positions (8)

TickerIssuerNotional
Invitae Corporation$135.0M
IMGNImmunoGen, Inc.$28.7M
DAWNDay One Biopharmaceuticals, Inc.$11.9M
COGTCogent Biosciences, Inc.$11.6M
VSTMVerastem, Inc.$9.9M
MREOMereo BioPharma Group PLC$4.7M
GRCLGracell Biotechnologies Inc.$3.8M
CYPHLeap Therapeutics, Inc.$3.7M

Exited Positions (8)

TickerIssuerNotional
BPMCBlueprint Medicines Corporation$15.0M
VSTMXXXXVerastem, Inc.$10.6M
TLISTalis Biomedical Corporation$3.7M
LPTXLeap Therapeutics, Inc.$2.5M
ATRAAtara Biotherapeutics, Inc.$2.2M
VERUXXXXVeru Inc.$1.9M
TCRRTCR2 Therapeutics Inc.$1.1M
BLCMBellicum Pharmaceuticals, Inc.$0.1M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
GLUEMonte Rosa Therapeutics, Inc.$17.8M+706.2%
RLAYRelay Therapeutics, Inc.$9.9M+308.5%
ROIVRoivant Sciences Ltd.$59.8M+97.4%+248.5%
RAREUltragenyx Pharmaceutical Inc.$17.2M+66.3%
ABCLAbCellera Biologics Inc.$27.5M+57.4%+25.5%
KYMRKymera Therapeutics, Inc.$15.3M+51.9%+393.7%
KALAKala Pharmaceuticals, Inc.$0.5M+51.3%
ATHAAthira Pharma, Inc.$3.4M+34.2%

Trimmed (8)

TickerIssuerNotionalShares Ξ”
FGENFibroGen, Inc.$-48.6M-91.0%
VERAVera Therapeutics, Inc.$-0.2M-56.1%
KRYSKrystal Biotech, Inc.$-4.3M-43.9%
MRSNMersana Therapeutics, Inc.$-4.2M-42.4%
NKTXNkarta, Inc.$-0.8M-32.2%
RNAMAvidity Biosciences, Inc.$-6.5M-20.4%
DSGNDesign Therapeutics, Inc.$-0.5M-20.2%
VINCVincerx Pharma, Inc.$0.0M-6.5%
← Back to Hedge Funds